Cellerant Therapeutics Inc., of San Carlos, Calif., started a Phase I/II trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia. CLT-008 is an allogeneic cell-based therapy designed to provide hematopoietic support following high-dose chemotherapy or radiation exposure.